Company Encyclopedia
View More
name
MicuRx
688373.SH
Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour. Shanghai MicuRx Pharmaceutical Co., Ltd. was founded in 2007 and is based in Shanghai, China.
1.556 T
688373.SHMarket value -Rank by Market Cap -/-

Financial Score

28/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking74/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-83.12%E
    • Profit Margin-250.89%E
    • Gross Margin85.05%A
  • Growth ScoreC
    • Revenue YoY13.85%B
    • Net Profit YoY26.71%B
    • Total Assets YoY-25.12%E
    • Net Assets YoY-54.63%E
  • Cash ScoreC
    • Cash Flow Margin-39.86%D
    • OCF YoY13.85%B
  • Operating ScoreD
    • Turnover0.16D
  • Debt ScoreD
    • Gearing Ratio64.57%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    MicuRx: Net loss of 54.8617 million yuan in the third quarter

    MicuRx announced that its revenue for the third quarter was 37.0155 million yuan, a year-on-year increase of 0.52%; the net profit loss was 54.8617 million yuan. The revenue for the first three quarters was 104 million yuan, a year-on-year increase of 6.58%; the net profit loss was 194 million yuan

    Zhitong·
    SH
    688373
    -0.16%
    Zhitong·
    SH
    688373
    -0.16%

    MicuRx Pharmaceuticals has reached a strategic cooperation agreement with Pengbo Biotech for the joint development of ADC drugs

    According to MicuRx, recently, MicuRx officially signed the "ADC Drug Joint Development Strategic Cooperation Agreement" with Nanjing Pengbo Biotechnology Co., Ltd. Both parties will fully leverage their respective advantages in the "toxin-linker" platform and the "antibody development platform" to jointly discover, research, and develop several innovative targeted antibody-drug conjugates

    Zhitong·
    SH
    688373
    -0.16%
    Zhitong·
    SH
    688373
    -0.16%

    MicuRx shareholders Genie Pharma propose to add a temporary proposal regarding the removal and election of directors

    MicuRx's shareholder Genie Pharma has proposed to add an interim proposal at the second extraordinary general meeting of shareholders in 2025, involving the removal of directors ZHENGYU YUAN, Li Zhile, Wu Pancheng, and the election of new directors Yang Zongfan, Wang Yong, and Xu Yuchao. The general meeting of shareholders originally scheduled for October 9, 2025, will review all proposals, including the new proposal

    Zhitong·
    SH
    688373
    -0.16%
    Zhitong·
    SH
    688373
    -0.16%

    MicuRx shareholders Genie Pharma publicly solicit votes to oppose certain proposals

    MicuRx's shareholder Genie Pharma voted against several proposals for the second extraordinary general meeting in 2025, holding 71.5728 million shares, accounting for 10.92% of the total shares. The solicitation period for voting rights is from September 25, 2025, to October 6, 2025. Reasons for opposition include the uncertainty of funds from Haiqing Pharmaceutical's private placement, risks of mixed sales channels, and the progress of fundraising projects not meeting expectations

    Zhitong·
    SH
    688373
    -0.16%
    Zhitong·
    SH
    688373
    -0.16%

    MicuRx Pharmaceuticals signed a strategic cooperation agreement with Haiqing Pharmaceuticals

    MicuRx Pharmaceuticals has signed a strategic cooperation agreement with Nanjing Haiqing Pharmaceuticals. The two parties will collaborate in areas such as market and customer network, and service value enhancement. The goal is to integrate market resources to promote the sales of the company's products in new regions and hospitals, with expected sales revenues of 260 million yuan, 388 million yuan, and 600 million yuan for the years 2026-2028, respectively. The two parties will also establish a product innovation cooperation platform, focusing on research in disease prevention and treatment, jointly developing new products, and promoting the internationalization of Chinese pharmaceutical companies

    Zhitong·
    SH
    688373
    -0.16%
    Zhitong·
    SH
    688373
    -0.16%
    © 2025 Longbridge｜Disclaimer